학술논문

Burosumab, a Fully Human Anti-FGF23 Monoclonal Antibody, for X-Linked Hypophosphatemia (XLH): Sustained Improvement in Two Phase 2 Trials in Affected Children 1-12 Years Old
Document Type
Journal
Source
HORMONE RESEARCH IN PAEDIATRICS; 2018, 90 p30-p30, 1p. Supplement: 1
Subject
Language
English
ISSN
16632826